Diaz M, Tran J, Rose D, Wei A, Lakshmipathy D, Lipner S
Nutrients. 2025; 17(2).
PMID: 39861486
PMC: 11767946.
DOI: 10.3390/nu17020357.
Zhang W, Zhai S, Dou J, Zhang S, Liu H
Arch Dermatol Res. 2025; 317(1):252.
PMID: 39821379
DOI: 10.1007/s00403-024-03717-3.
Yuan Y, Zhang Y, Zheng L, Gu X, Yu S, Sun X
Syst Rev. 2024; 13(1):250.
PMID: 39358803
PMC: 11445846.
DOI: 10.1186/s13643-024-02653-7.
Solimani F, Ghoreschi K
Dermatologie (Heidelb). 2024; 75(10):781-790.
PMID: 39212722
DOI: 10.1007/s00105-024-05406-8.
Hussein A, Shams A, Hosny N, Elrosasy A, Kobtan M, Shafik Y
Arch Dermatol Res. 2024; 316(8):518.
PMID: 39134884
DOI: 10.1007/s00403-024-03267-8.
Identifying the genetic association between common rheumatic diseases and vitiligo.
Zhao M, Zhang Y, Sun G
Skin Res Technol. 2024; 30(7):e13846.
PMID: 38967217
PMC: 11224917.
DOI: 10.1111/srt.13846.
Vitiligo: Pathogenesis and New and Emerging Treatments.
Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G
Int J Mol Sci. 2023; 24(24).
PMID: 38139134
PMC: 10743634.
DOI: 10.3390/ijms242417306.
Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.
Pala V, Ribero S, Quaglino P, Mastorino L
J Clin Med. 2023; 12(23).
PMID: 38068541
PMC: 10707156.
DOI: 10.3390/jcm12237486.
Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream.
Howell M, Kuo F, Rumberger B, Boarder E, Sun K, Butler K
JID Innov. 2023; 3(6):100230.
PMID: 37840766
PMC: 10568564.
DOI: 10.1016/j.xjidi.2023.100230.
NRF2 in the Epidermal Pigmentary System.
Ogawa T, Ishitsuka Y
Biomolecules. 2023; 13(1).
PMID: 36671405
PMC: 9855619.
DOI: 10.3390/biom13010020.
Study of Novel Furocoumarin Derivatives on Anti-Vitiligo Activity, Molecular Docking and Mechanism of Action.
Niu C, Zang D, Aisa H
Int J Mol Sci. 2022; 23(14).
PMID: 35887323
PMC: 9316487.
DOI: 10.3390/ijms23147959.
A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo.
White C, Miller R
J Clin Aesthet Dermatol. 2022; 15(4):20-25.
PMID: 35465035
PMC: 9017670.
The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.
He S, Xu J, Wu J
Oxid Med Cell Longev. 2022; 2022:8796735.
PMID: 35096274
PMC: 8791757.
DOI: 10.1155/2022/8796735.
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F, Liu F, Gao L
Front Immunol. 2021; 12:790125.
PMID: 34868078
PMC: 8636851.
DOI: 10.3389/fimmu.2021.790125.
Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response.
Yang Q, Zhang G, Su M, Leung G, Lui H, Zhou P
Front Immunol. 2021; 12:613031.
PMID: 33815367
PMC: 8015777.
DOI: 10.3389/fimmu.2021.613031.
Vitiligo, From Physiopathology to Emerging Treatments: A Review.
Migayron L, Boniface K, Seneschal J
Dermatol Ther (Heidelb). 2020; 10(6):1185-1198.
PMID: 32949337
PMC: 7649199.
DOI: 10.1007/s13555-020-00447-y.
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.
Boukhedouni N, Martins C, Darrigade A, Drullion C, Rambert J, Barrault C
JCI Insight. 2020; 5(11).
PMID: 32369451
PMC: 7308056.
DOI: 10.1172/jci.insight.133772.
Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J
Front Immunol. 2020; 11:344.
PMID: 32194562
PMC: 7064060.
DOI: 10.3389/fimmu.2020.00344.
Reliability and validity of the Vitiligo Signs of Activity Score (VSAS).
van Geel N, Passeron T, Wolkerstorfer A, Speeckaert R, Ezzedine K
Br J Dermatol. 2020; 183(5):883-890.
PMID: 32064583
PMC: 7687072.
DOI: 10.1111/bjd.18950.
Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.
Montilla A, Gomez-Garcia F, Gomez-Arias P, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B
Dermatol Ther (Heidelb). 2019; 9(4):655-683.
PMID: 31606872
PMC: 6828894.
DOI: 10.1007/s13555-019-00329-y.
